The US Food and Drug Administration (FDA) has given approval to a new once-a-day drug intended to treat relapsing forms of multiple sclerosis (MS), the agency announced on 12 September. Multiple ...
Multiple sclerosis (MS) is most prevalent in Northern Europe and Canada, and more common in the northernmost latitudes. In ...
The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...
A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...
Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...
Hosted on MSN
For women with primary progressive MS, could bestselling drug be doing more harm than good?
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a ...
Scientists hunting for treatments and cures for multiple sclerosis may have found an unlikely ally — the yak. The high-altitude, cold-hardy relative of the cow could be the key to a medical ...
ZURICH, April 22 (Reuters) - Swiss drugmaker Roche (ROPC.S), opens new tab on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting ...
BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche (ROG.S), opens new tab said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results